Source: BioSpace

Gemphire Therapeutics: Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals

Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals,

Read full article »
Gemphire Therapeutics's Competitors | Gemphire Therapeutics's News | Gemphire Therapeutics's Financials
Stay up-to-date with the latest news on Gemphire Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Stephen Gullans's photo - President & CEO of Gemphire Therapeutics

President & CEO

Stephen Gullans

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Gemphire Therapeutics